{"id":"prednisone-capsules","safety":{"commonSideEffects":[{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Increased appetite"},{"rate":null,"effect":"Mood changes (irritability, anxiety)"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Osteoporosis (with chronic use)"},{"rate":null,"effect":"Immunosuppression / increased infection risk"},{"rate":null,"effect":"Gastrointestinal upset"},{"rate":null,"effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL15720","moleculeType":"Small molecule","molecularWeight":"358.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Prednisone acts as a glucocorticoid receptor agonist, entering cells and binding to cytoplasmic glucocorticoid receptors. This complex translocates to the nucleus where it modulates gene transcription, leading to decreased production of pro-inflammatory cytokines, reduced immune cell proliferation and migration, and suppression of inflammatory responses. It is commonly used to manage autoimmune and inflammatory conditions across multiple organ systems.","oneSentence":"Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:53.711Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Systemic lupus erythematosus"},{"name":"Polymyalgia rheumatica"},{"name":"Giant cell arteritis"},{"name":"Asthma"},{"name":"Chronic obstructive pulmonary disease exacerbations"},{"name":"Adrenocortical insufficiency"},{"name":"Allergic reactions"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT07412470","phase":"PHASE2, PHASE3","title":"A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-03-13","conditions":"Kidney Transplant Rejection","enrollment":526},{"nctId":"NCT06934915","phase":"EARLY_PHASE1","title":"Prednisone in Adults With an Immune-Mediated Subtype of Autism Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"Christopher John McDougle, M.D.","startDate":"2026-11","conditions":"Autism Spectrum Disorder, Autism Spectrum Disorders, Autistic Disorder","enrollment":32},{"nctId":"NCT03748641","phase":"PHASE3","title":"A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-01-25","conditions":"Castration-Resistant Prostatic Cancer","enrollment":765},{"nctId":"NCT05811351","phase":"PHASE2","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-06","conditions":"Geographic Atrophy","enrollment":305},{"nctId":"NCT04179864","phase":"PHASE1, PHASE2","title":"A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer","status":"TERMINATED","sponsor":"Epizyme, Inc.","startDate":"2019-11-18","conditions":"Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":102},{"nctId":"NCT04623541","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-25","conditions":"Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome","enrollment":195},{"nctId":"NCT05283720","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-06-14","conditions":"Non-Hodgkin Lymphoma","enrollment":496},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT06894511","phase":"PHASE2","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-09-11","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":7},{"nctId":"NCT02861573","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-11-17","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":1200},{"nctId":"NCT04729114","phase":"PHASE1","title":"A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2021-06-14","conditions":"Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer","enrollment":174},{"nctId":"NCT07311694","phase":"PHASE3","title":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-02-02","conditions":"PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer","enrollment":370},{"nctId":"NCT04294641","phase":"PHASE2","title":"Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-10","conditions":"Chronic GVHD","enrollment":10},{"nctId":"NCT06846463","phase":"PHASE2","title":"Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-05-27","conditions":"Diffuse Large B-cell Lymphoma, DLBCL - Diffuse Large B Cell Lymphoma","enrollment":21},{"nctId":"NCT05457257","phase":"PHASE4","title":"Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-07-29","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT04446117","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2020-10-19","conditions":"Metastatic Prostate Cancer, Prostate Adenocarcinoma","enrollment":575},{"nctId":"NCT04214626","phase":"PHASE2","title":"R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Henan Cancer Hospital","startDate":"2020-01-05","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT06841705","phase":"PHASE2","title":"Early Vedolizumab as First-Line for Immune-Related Colitis Therapy Trial","status":"RECRUITING","sponsor":"Shilpa Grover, MD, MPH","startDate":"2025-07-15","conditions":"Immune Checkpoint Inhibitor-Related Colitis","enrollment":80},{"nctId":"NCT03790332","phase":"PHASE1, PHASE2","title":"Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2018-11-19","conditions":"Chronic Graft Versus Host Disease","enrollment":59},{"nctId":"NCT04520451","phase":"PHASE2","title":"Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Participants","status":"COMPLETED","sponsor":"Principia Biopharma, a Sanofi Company","startDate":"2020-08-22","conditions":"Immunoglobulin G4 Related Disease","enrollment":27},{"nctId":"NCT07049172","phase":"NA","title":"Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome","status":"COMPLETED","sponsor":"Wuhan Children's Hospital","startDate":"2021-01-01","conditions":"Nephrotic Syndrome in Children","enrollment":91},{"nctId":"NCT03568656","phase":"PHASE1, PHASE2","title":"Study to Evaluate CCS1477 in Advanced Tumours","status":"COMPLETED","sponsor":"CellCentric Ltd.","startDate":"2018-07-23","conditions":"Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer","enrollment":220},{"nctId":"NCT04496479","phase":"PHASE2","title":"Allogenic Hepatocyte Transplantation Into Periduodenal Lymph Nodes","status":"RECRUITING","sponsor":"LyGenesis, Inc.","startDate":"2022-03-11","conditions":"End Stage Liver Disease","enrollment":12},{"nctId":"NCT06633419","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-12-18","conditions":"Healthy","enrollment":14},{"nctId":"NCT01974440","phase":"PHASE3","title":"A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-01-31","conditions":"Lymphoma","enrollment":403},{"nctId":"NCT03834519","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-05-02","conditions":"Prostatic Neoplasms","enrollment":793},{"nctId":"NCT06730542","phase":"PHASE1","title":"Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma","status":"RECRUITING","sponsor":"Juan P. Alderuccio, MD","startDate":"2025-04-17","conditions":"CNS Lymphoma","enrollment":20},{"nctId":"NCT03412565","phase":"PHASE2","title":"A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-04-26","conditions":"Multiple Myeloma","enrollment":265},{"nctId":"NCT05867329","phase":"PHASE4","title":"Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Berinstein, Jeffrey","startDate":"2023-09-30","conditions":"Ulcerative Colitis Acute","enrollment":162},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT02994927","phase":"PHASE3","title":"A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis","status":"COMPLETED","sponsor":"Amgen","startDate":"2017-03-15","conditions":"ANCA-Associated Vasculitis","enrollment":331},{"nctId":"NCT01855750","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-09-03","conditions":"Lymphoma","enrollment":838},{"nctId":"NCT01715285","phase":"PHASE3","title":"A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-02-12","conditions":"Prostate Neoplasms","enrollment":1209},{"nctId":"NCT03210688","phase":"PHASE4","title":"Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2018-05-01","conditions":"Minimal Change Disease, Nephrotic Syndrome","enrollment":71},{"nctId":"NCT05201248","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Therapies in Adult Participants in China With B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2022-03-10","conditions":"B-Cell Non-Hodgkin Lymphoma","enrollment":49},{"nctId":"NCT04691804","phase":"PHASE3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-03-18","conditions":"Metastatic Castration-Resistant Prostate Cancer (mCRPC)","enrollment":496},{"nctId":"NCT02631603","phase":"PHASE2","title":"Stop Exogenous Allergic Alveolitis (EAA) in Childhood","status":"TERMINATED","sponsor":"Matthias Griese","startDate":"2015-04","conditions":"Hypersensitivity Pneumonitis, Exogenous Allergic Alveolitis","enrollment":4},{"nctId":"NCT04812366","phase":"PHASE2","title":"Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer","status":"RECRUITING","sponsor":"University of British Columbia","startDate":"2021-09-21","conditions":"Prostate Cancer","enrollment":315},{"nctId":"NCT01650194","phase":"PHASE2","title":"A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-07-09","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":60},{"nctId":"NCT02921789","phase":"PHASE2","title":"Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-05-22","conditions":"Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)","enrollment":67},{"nctId":"NCT05714670","phase":"PHASE2","title":"The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-04-01","conditions":"Lupus Nephritis, SLE Nephritis","enrollment":72},{"nctId":"NCT04745832","phase":"PHASE3","title":"Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)","status":"TERMINATED","sponsor":"MEI Pharma, Inc.","startDate":"2021-08-13","conditions":"Follicular Lymphoma (FL), Non Hodgkin Lymphoma, Marginal Zone Lymphoma","enrollment":82},{"nctId":"NCT02457221","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis","status":"COMPLETED","sponsor":"Astellas Pharma China, Inc.","startDate":"2015-03-10","conditions":"Lupus Nephritis","enrollment":314},{"nctId":"NCT04701528","phase":"PHASE2","title":"Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Leiden University Medical Center","startDate":"2020-11-15","conditions":"Covid19, Kidney Transplant Infection","enrollment":20},{"nctId":"NCT06554639","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-11","conditions":"Prostatic Neoplasms","enrollment":12},{"nctId":"NCT04060394","phase":"PHASE1, PHASE2","title":"Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC","status":"COMPLETED","sponsor":"Laekna Limited","startDate":"2019-09-13","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":49},{"nctId":"NCT04974216","phase":"PHASE2","title":"Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2021-12-20","conditions":"DLBCL","enrollment":71},{"nctId":"NCT01393639","phase":"PHASE2","title":"Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09-27","conditions":"Rheumatoid Arthritis","enrollment":323},{"nctId":"NCT02453009","phase":"PHASE2","title":"Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Santa Chiara Hospital","startDate":"2014-10","conditions":"Prostatic Neoplasms","enrollment":246},{"nctId":"NCT04677855","phase":"PHASE1","title":"Study of PCUR-101 in Combination With ADT in Patients With mCRPC","status":"TERMINATED","sponsor":"Pellficure Pharmaceuticals, Inc","startDate":"2021-03-30","conditions":"Prostate Cancer","enrollment":7},{"nctId":"NCT03752307","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses","status":"COMPLETED","sponsor":"University of New Mexico","startDate":"2019-02-15","conditions":"Multiple Sclerosis","enrollment":2},{"nctId":"NCT00576069","phase":"","title":"Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma","status":"RECRUITING","sponsor":"Gelb, Arthur F., M.D.","startDate":"2007-10-25","conditions":"Asthma","enrollment":60},{"nctId":"NCT02987543","phase":"PHASE3","title":"Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-02-06","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":387},{"nctId":"NCT01995513","phase":"PHASE4","title":"Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-10-22","conditions":"Prostate Cancer","enrollment":509},{"nctId":"NCT04628988","phase":"PHASE1","title":"A Study of CC-90011 and Comparators in Participants With Prostate Cancer","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-07-28","conditions":"Prostatic Neoplasms","enrollment":6},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT03732586","phase":"NA","title":"Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis","status":"COMPLETED","sponsor":"Hospital General Dr. Manuel Gea González","startDate":"2018-09-30","conditions":"Alcoholic Hepatitis","enrollment":40},{"nctId":"NCT03003520","phase":"PHASE2","title":"A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-02-28","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":46},{"nctId":"NCT02959944","phase":"PHASE3","title":"Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-05-11","conditions":"Chronic Graft Versus Host Disease","enrollment":193},{"nctId":"NCT05003713","phase":"PHASE1","title":"Single and Multiple Ascending Dose Study of CORT125236 in Healthy Participants","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2021-08-03","conditions":"Healthy","enrollment":82},{"nctId":"NCT01332097","phase":"PHASE2","title":"Safety & Efficacy of BCT197A2201 in COPD Patients Presenting With an Exacerbation","status":"COMPLETED","sponsor":"Mereo BioPharma","startDate":"2011-03","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":183},{"nctId":"NCT03782532","phase":"PHASE3","title":"Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-01-25","conditions":"Asthma","enrollment":486},{"nctId":"NCT02485691","phase":"PHASE4","title":"Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-09","conditions":"Prostate Cancer Metastatic","enrollment":255},{"nctId":"NCT03099122","phase":"PHASE4","title":"A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant","status":"COMPLETED","sponsor":"Sanofi","startDate":"2017-08-16","conditions":"End-stage Renal Disease","enrollment":115},{"nctId":"NCT02268175","phase":"PHASE2","title":"Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2014-10","conditions":"Prostate Adenocarcinoma, Prostate Cancer, High Risk Prostate Cancer","enrollment":75},{"nctId":"NCT04795583","phase":"PHASE3","title":"Corticosteroids for COVID-19","status":"WITHDRAWN","sponsor":"University of Alberta","startDate":"2021-08-01","conditions":"Covid19","enrollment":""},{"nctId":"NCT03532022","phase":"PHASE3","title":"Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy","status":"WITHDRAWN","sponsor":"Neurocrine UK Limited","startDate":"2018-10-04","conditions":"Congenital Adrenal Hyperplasia","enrollment":""},{"nctId":"NCT04974996","phase":"PHASE1","title":"A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)","status":"WITHDRAWN","sponsor":"ADC Therapeutics S.A.","startDate":"2022-02-01","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":""},{"nctId":"NCT03600805","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-11-20","conditions":"Giant Cell Arteritis","enrollment":83},{"nctId":"NCT05200312","phase":"PHASE2","title":"A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2022-02-01","conditions":"Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":36},{"nctId":"NCT01085097","phase":"PHASE2","title":"A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2010-09-01","conditions":"Lupus Nephritis","enrollment":46},{"nctId":"NCT04672512","phase":"PHASE1","title":"Single and Multiple Ascending Dose Study of CORT125329 in Healthy Participants","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2020-10-23","conditions":"Healthy","enrollment":115},{"nctId":"NCT04249323","phase":"PHASE1","title":"Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2020-01-27","conditions":"Healthy Adults","enrollment":110},{"nctId":"NCT03194321","phase":"PHASE4","title":"Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in Human Leukocyte Antigen (HLA) Sensitized Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-09-11","conditions":"End Stage Renal Disease","enrollment":20},{"nctId":"NCT05156450","phase":"PHASE2","title":"TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2022-01-01","conditions":"Prostatic Neoplasms, Castration-Resistant, Drug Therapy, Combination","enrollment":30},{"nctId":"NCT02277223","phase":"PHASE3","title":"Curcumin in Pediatric Ulcerative Colitis","status":"WITHDRAWN","sponsor":"Schneider Children's Medical Center, Israel","startDate":"2020-03-01","conditions":"Ulcerative Colitis","enrollment":""},{"nctId":"NCT03304626","phase":"PHASE2","title":"Budesonide for Liver Transplant Immune Suppression","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2017-06-27","conditions":"Acute Cellular Graft Rejection, New Onset Diabetes After Transplant","enrollment":40},{"nctId":"NCT02716818","phase":"PHASE3","title":"Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Neurocrine UK Limited","startDate":"2016-02-22","conditions":"Congenital Adrenal Hyperplasia","enrollment":122},{"nctId":"NCT01634061","phase":"PHASE1","title":"Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-09","conditions":"Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT00290498","phase":"PHASE2","title":"Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-08-01","conditions":"Lymphoma","enrollment":67},{"nctId":"NCT02370550","phase":"PHASE4","title":"Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2015-03","conditions":"Sjogren's Syndrome","enrollment":240},{"nctId":"NCT03828682","phase":"PHASE4","title":"Veloxis de Novo Kidney Transplant ECSWD","status":"UNKNOWN","sponsor":"Simon Tremblay, PharmD, PhD","startDate":"2019-06-21","conditions":"Kidney Transplantation, Immunosuppression","enrollment":60},{"nctId":"NCT03610685","phase":"PHASE4","title":"Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2018-10-19","conditions":"Asthma","enrollment":33},{"nctId":"NCT02836496","phase":"PHASE3","title":"Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-03-07","conditions":"Hypereosinophilic Syndrome","enrollment":108},{"nctId":"NCT02953873","phase":"PHASE4","title":"Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2017-05-05","conditions":"Immunosuppression","enrollment":25},{"nctId":"NCT00689936","phase":"PHASE3","title":"Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma","status":"COMPLETED","sponsor":"Celgene","startDate":"2008-08-21","conditions":"Multiple Myeloma","enrollment":1623},{"nctId":"NCT01536535","phase":"PHASE4","title":"Predicting Response to Standardized Pediatric Colitis Therapy","status":"COMPLETED","sponsor":"Connecticut Children's Medical Center","startDate":"2012-07-10","conditions":"Ulcerative Colitis","enrollment":431},{"nctId":"NCT03508635","phase":"PHASE1","title":"CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2014-09","conditions":"Healthy","enrollment":130},{"nctId":"NCT02034552","phase":"PHASE2","title":"A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-03-07","conditions":"Prostatic Neoplasms","enrollment":68},{"nctId":"NCT00946270","phase":"PHASE2","title":"Pomalidomide for Myelofibrosis Patients","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-07-22","conditions":"Polycythemia Vera, Thrombocythemia","enrollment":70},{"nctId":"NCT03315338","phase":"PHASE1","title":"First-in-human Study in Healthy Subjects","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2017-09-15","conditions":"Healthy","enrollment":143},{"nctId":"NCT00838214","phase":"PHASE2, PHASE3","title":"Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis","status":"COMPLETED","sponsor":"Dr. Falk Pharma GmbH","startDate":"2001-03","conditions":"Autoimmune Hepatitis","enrollment":208},{"nctId":"NCT03549663","phase":"NA","title":"Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2018-07-04","conditions":"Idiopathic Membranous Nephropathy","enrollment":108},{"nctId":"NCT01656187","phase":"PHASE4","title":"Attenuation of Corticosteroid Induced Hippocampal Changes","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2012-01","conditions":"Organic Memory Impairment","enrollment":46},{"nctId":"NCT02145598","phase":"PHASE2, PHASE3","title":"Treatment Optimization in Patients With Untreated Multiple Myeloma","status":"TERMINATED","sponsor":"Dr. med. Lars-Olof Muegge","startDate":"2013-08","conditions":"Multiple Myeloma","enrollment":85},{"nctId":"NCT02800447","phase":"NA","title":"Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2016-06","conditions":"Advanced Hodgkin's Lymphoma","enrollment":92},{"nctId":"NCT02908698","phase":"NA","title":"Effect of Oral Steroids on Skin Outcomes in Atopic Dermatitis","status":"TERMINATED","sponsor":"McMaster University","startDate":"2017-01-24","conditions":"Atopic Dermatitis","enrollment":16},{"nctId":"NCT03335956","phase":"PHASE1","title":"CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)","status":"COMPLETED","sponsor":"Corcept Therapeutics","startDate":"2017-09-21","conditions":"Healthy","enrollment":48},{"nctId":"NCT01522443","phase":"PHASE3","title":"Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer","status":"TERMINATED","sponsor":"Exelixis","startDate":"2012-03","conditions":"Prostate Cancer, Castration Resistant Prostate Cancer, Pain","enrollment":119},{"nctId":"NCT01605227","phase":"PHASE3","title":"Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100","status":"COMPLETED","sponsor":"Exelixis","startDate":"2012-07","conditions":"Prostate Cancer, Castration Resistant Prostate Cancer, Pain","enrollment":1028}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ATRIAL FIBRILLATION"},{"count":1,"reaction":"CATARACT"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"FATIGUE"},{"count":1,"reaction":"HYPERGLYCAEMIA"},{"count":1,"reaction":"LOCALISED INFECTION"},{"count":1,"reaction":"MALAISE"},{"count":1,"reaction":"NAUSEA"},{"count":1,"reaction":"NEUTROPENIA"}],"_approvalHistory":[],"publicationCount":58,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Prednisone capsules","genericName":"Prednisone capsules","companyName":"Teva Branded Pharmaceutical Products R&D, Inc.","companyId":"teva-branded-pharmaceutical-products-r-d-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors in cells. Used for Rheumatoid arthritis, Systemic lupus erythematosus, Polymyalgia rheumatica.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}